Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos Group's revenue per share for the
six
months ended in Dec. 2025 was $22.06.
Ebos Group's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was $41.95.
Warning Sign:
Ebos Group Ltd revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue Per Share Growth Rate of Ebos Group was -1.30% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -0.20% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was 4.10% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 5.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Ebos Group's Revenue per Share or its related term are showing as below:
EBOSF'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.7 Med: 9.9 Max: 45.2
Current: -0.2
During the past 13 years, Ebos Group's highest 3-Year average Revenue Per Share Growth Rate was 45.20% per year. The lowest was -0.70% per year. And the median was 9.90% per year.
EBOSF's 3-Year Revenue Growth Rate is ranked worse than 65.79% of 114
companies
in the Medical Distribution industry
Industry Median: 4.45
vs EBOSF: -0.20
Ebos Group (OTCPK:EBOSF) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Ebos Group Revenue per Share Related Terms
Ebos Group Revenue per Share Historical Data
* Premium members only.
The historical data trend for Ebos Group's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBOSF vs MCK, COR, CAH: Revenue per Share Comparison
For the Medical Distribution subindustry, Ebos Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group PS Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Ebos Group's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Ebos Group's Revenue Per Share for the fiscal year that ended in Jun. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $41.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (EBOSF) has a Revenue per Share of $41.95 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on Ebos Group and its competitors. According to the industry distribution chart, Ebos Group ranks #75 out of 114 companies in the Medical Distribution industry, placing it in the top 65.8%.
Is Ebos Group's Revenue per Share too high?
Ebos Group's current Revenue per Share is $41.95. The Medical Distribution industry median Revenue per Share is 4.45. Ebos Group's value of $41.95 is 842.7% above this industry median. Based on the distribution chart, Ebos Group ranks #75 out of 114 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Ebos Group has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Revenue per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #75 out of 114 companies for Revenue per Share. This places Ebos Group in the lower half of its industry. The industry median Revenue per Share is 4.45. Ebos Group's value of $41.95 is 842.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Distribution company?
The median Revenue per Share among Medical Distribution companies is 4.45, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Revenue per Share of $41.95 is 842.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Revenue per Share is 4.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Revenue per Share is $41.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Ebos Group (EBOSF) has a current Revenue per Share of $41.95. The stock's GF Value™ is $43.41, compared to a current price of $23.75 — trading 45.3% below its estimated fair value. The current Revenue per Share is $41.95 and 842.7% above the Medical Distribution industry median of 4.45. Ebos Group's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Ebos Group (EBOSF), the current Revenue per Share is $41.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (EBOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of $23.75 is trading 45.3% below its estimated GF Value™ of $43.41.
Key valuation signals for EBOSF:
Revenue per Share: $41.95
GF Value™: $43.41 vs. price of $23.75 (45.3% below fair value)
Industry Position: 842.7% above the Medical Distribution median (#75 of 114)
No single metric tells the full story. See the EBOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
85GF Score
Get the complete analysis for EBOSF
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EBOSF has been successfully added to your 
